AstraZeneca PLC has released its third-quarter results for 2026, showcasing strong financial performance. The company reported a 7% increase in total revenue and a 14% rise in core earnings per share (EPS). This growth is attributed to the company's diverse therapy areas and global presence, which have driven commercial momentum.

The results are significant as they highlight AstraZeneca's ability to navigate challenges in the pharmaceutical industry, particularly amidst the loss of exclusivity for some products. CEO Pascal Soriot emphasized the company's achievements, stating, “In the first nine months we saw strong commercial momentum with total revenue up 7% and Core EPS up 14.”

Background

AstraZeneca PLC operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the New York Stock Exchange under the ticker AZN. AstraZeneca has a rich history of innovation in the pharmaceutical sector and has been a key player in developing treatments across various therapeutic areas.

What the Filing Says

The recent filing, dated October 30, 2026, details AstraZeneca's third-quarter results for the year. The report indicates a total revenue of $46.88 billion for the quarter, with a notable increase in core EPS to $8.00. The company also reported 12 positive Phase III programme readouts this year, showcasing its commitment to advancing new therapies.

Impact

This performance may affect various stakeholders, including investors, healthcare providers, and patients. The positive results could bolster investor confidence and attract further investment into AstraZeneca. Additionally, the successful drug approvals and ongoing clinical trials may enhance treatment options available to patients.

What's Next

AstraZeneca has reaffirmed its total revenue and core EPS guidance for the fiscal year 2026, indicating that it expects a mid-to-high single-digit percentage increase in revenue and a low double-digit percentage increase in core EPS. The filing does not specify any upcoming events or changes beyond this guidance.